Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.49 |
| ▸ | METAP2 | P50579 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030763 | 0.84 | AXL (0.42) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL23564663 | 0.81 | AXL (0.40) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL28799165 | 0.80 | NOS1 (0.50) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL18456308 | 0.80 | AXL (0.50) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL29980240 | 0.80 | NOS1 (0.50) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL5404571 | 0.80 | AXL (0.50) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL5417197 | 0.80 | METAP2 (0.47) | AXLTRPA1METAP2CYP1A2IDO1 | |
| SCHEMBL31411470 | 0.76 | TRPA1 (0.50) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL2427200 | 0.76 | AXL (0.46) | AXLTRPA1METAP2CYP1A2CDK2 | |
| SCHEMBL12293667 | 0.76 | AXL (0.46) | AXLTRPA1METAP2CYP1A2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | AXL 4855/4885TRPA1 4824/4885METAP2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.